Here’s Why Wall Street is Bullish on TransMedics Group (TMDX)

Group 1 - TransMedics Group, Inc. (NASDAQ:TMDX) has received conditional approval from the US FDA for its Investigational Device Exemption, enabling the start of its Next-Generation OCS ENHANCE Heart trial [1] - The trial consists of two parts: the first part focuses on prolonged heart perfusion using the OCS Heart System, while the second part aims to demonstrate that OCS Heart perfusion is superior to traditional cold storage methods for hearts donated after brain death [2] - Analysts have shown strong support for TMDX stock following the FDA approval, with TD Cowen's Josh Jennings reiterating a Buy rating and a price target of $170, and Piper Sandler's Matthew O'Brien also maintaining a Buy rating with a price target of $145 [3] Group 2 - TransMedics Group, Inc. is recognized as a medical technology company that innovates organ transplant therapy for patients suffering from end-stage lung, heart, and liver failure [3]